Overview

Denosumab and Male Infertility: a RCT

Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
To determine the significance of systemic RANKL inhibition for male reproduction, conducting a clinical controlled randomized double blinded intervention study on infertile men, to investigating whether Denosumab (Prolia) can increase semen quality and to investigate what subgroup of infertile men that might benefit from treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Martin Blomberg Jensen
Treatments:
Denosumab